CTS-2090 / Histogen - LARVOL DELTA

Histogen Announces Issuance of US Patent Covering CTS-2090 Methods of Use (GlobeNewswire) - "We believe this key patent provides broad coverage for Histogen’s portfolio of highly selective and orally active anti-inflammatory caspase inhibitors, including CTS-2090. This patent includes information that CTS-2090 has demonstrated potent oral activity in a well characterized model of ulcerative colitis. Importantly, CTS-2090 provided statistically significant protection against inflammation-driven damage to the lining of the GI tract and also protected against loss of body weight."

Patent • Immunology

Conatus Late-breaker Oral Presentation at EASL Meeting Details Results of ENCORE-PH Phase 2b Clinical Trial in Patients with NASH Cirrhosis and Severe Portal Hypertension (GlobeNewswire, Conatus Pharmaceuticals Inc.) - The oral presentation at EASL entitled, “Multicenter, Double-blind, Placebo-controlled, Randomized Trial of Emricasan in Subjects with NASH Cirrhosis and Severe Portal Hypertension (PH),” (#LB01) detailed results from the company’s Phase 2b ENCORE-PH clinical trial of emricasan, the company’s first-in-class, orally active pan-caspase protease inhibitor. In collaboration with Novartis, Conatus is developing its lead in-licensed compound, emricasan, for the treatment of patients with NASH-driven chronic liver diseases.

Clinical • Clinical data • Late-breaking abstract • P2b data